JUN 23, 2020 10:00 AM PDT

Mesenchymal stromal or stem cell (MSC) workflow for efficient clinical translation: from automated GMP-compliant cell manufacturing to standardized phenotyping

Sponsored by: Miltenyi Biotec
C.E. Credits: P.A.C.E. CE Florida CE
  • Project Manager R&D, Miltenyi Biotec
      Kathrin Godthardt joined Miltenyi Biotec's R&D department in 2001. She received her Bachelor's Degree from University of Mainz and finished her thesis on characterization of endothelia progenitor cells at Miltenyi Biotec. She has a long-term experience on separation technologies, development of cell culture media and adaptation of separation and cultivation processes into clinical-scale closed systems for mesenchymal stem cells. Currently she is a Team Coordinator and Project Manager of the R&D Stem cell and Regenerative Medicine Group.


    DATE:  June 23, 2020

    TIME:  10:00am PT


    Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, such as COVID-19 disease. Several clinical trials have been started, and preliminary data hold great promise for clinical use and cell therapy for this severe disease. To facilitate efficient clinical translation, we developed an automated GMP-compliant cell manufacturing procedure using the integrated cell processing platform CliniMACS Prodigy®, which increases the level of process standardization and product safety. In this new adherent cell culture (ACC) system, sample cells are processed in a closed system, including automated density gradient centrifugation in case of human bone marrow sample, feeding, replating, expanding, and harvesting procedures. Clinical applications of MSCs for spine and joint pain needs only small amount stem cells injected locally. However, for systemic illness such as COVID-19, millions of cells are needed for IV inject. Our xeno-free MSC-Brew GMP Medium, following the recommendations of USP <1043> on ancillary materials, enables efficient isolation and expansion of MSCs from different tissue sources including human bone marrow, adipose tissue, and umbilical cord. Together with the ACC system,  over 200 million MSCs can be generated from single donor in just 14 days. Cultured MSCs need to go through strict quality control before any clinical applications. Our new MSC phenotyping kit, including 3 positive and 5 negative MSC markers based on ISCT standard, facilitates standardized and reliable phenotyping of cultured human MSCs from different tissue sources. The high-purity recombinant engineered antibodies (REAfinity™) in the kit ensures high lot-to-lot consistency and reproducible results in flow cytometry.  


    Learning objectives:

    • Discuss GMP grade serum-free and xeno-free Medium for efficient MSCs expansion from different tissue resources
    • Discuss Automated and closed Adherent Cell Culture (ACC) System for GMP scale MSC production
    • Discuss Standardized and reliable phenotyping of cultured MSCs



    Webinars will be available for unlimited on-demand viewing after live event.


    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    Show Resources
    • See more
    Connect with us